Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Payables (2016 - 2025)

Historic Payables for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $31.8 million.

  • Myriad Genetics' Payables rose 743.24% to $31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 743.24%. This contributed to the annual value of $32.3 million for FY2024, which is 2519.38% up from last year.
  • Latest data reveals that Myriad Genetics reported Payables of $31.8 million as of Q3 2025, which was up 743.24% from $30.9 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Payables ranged from a high of $39.8 million in Q2 2023 and a low of $15.7 million during Q3 2021
  • Over the past 5 years, Myriad Genetics' median Payables value was $29.6 million (recorded in 2021), while the average stood at $29.3 million.
  • In the last 5 years, Myriad Genetics' Payables plummeted by 3135.31% in 2021 and then surged by 8853.5% in 2022.
  • Myriad Genetics' Payables (Quarter) stood at $29.6 million in 2021, then decreased by 2.7% to $28.8 million in 2022, then decreased by 10.42% to $25.8 million in 2023, then increased by 25.19% to $32.3 million in 2024, then decreased by 1.55% to $31.8 million in 2025.
  • Its Payables stands at $31.8 million for Q3 2025, versus $30.9 million for Q2 2025 and $28.1 million for Q1 2025.